This trial is testing a new drug to see if it can effectively treat early stage breast cancer that is hormone receptor positive and human epidermal receptor 2 negative.
1 Primary · 8 Secondary · Reporting Duration: Baseline to Death from Any Cause (Approximately 10 Years)
Experimental Treatment
5637 Total Participants · 1 Treatment Group
Primary Treatment: Abemaciclib · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:New York | 100.0% |
18 - 65 | 100.0% |
University Hospitals Case Medical Center | 100.0% |
Did not meet criteria | 100.0% |